Conditions:  Advanced Malignant Solid Neoplasm;  Advanced Ovarian Carcinoma;  Metastatic Malignant Solid Neoplasm;  Metastatic Ovarian Carcinoma;  Recurrent Malignant Solid Neoplasm;  Refractory Malignant Solid Neoplasm;  Stage III Ovarian Cancer AJCC v8;  Stage IV Ovarian Cancer AJCC v8
Interventions:  Drug: BET Bromodomain Inhibitor ZEN-3694;  Drug: Talazoparib
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions:  Drug: BET Bromodomain Inhibitor ZEN-3694;  Drug: Talazoparib
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
